|View printer-friendly version|
|Quidel Bolsters Management Team with the Addition of Global Sales and Marketing Senior Vice President|
SAN DIEGO--(BUSINESS WIRE)--Sept. 15, 2003--Quidel Corporation (Nasdaq:QDEL), a leading provider of point-of-care (POC) rapid diagnostic tests, today announced it has named Matt T. Heindel senior vice president, global sales and marketing.
"Matt has a tremendous breadth of domestic and international sales, marketing and business development experience that will serve Quidel well in our pursuit of market leadership," said S. Wayne Kay, president and chief executive officer. "The addition of Matt to the Quidel management team is an important component of our plan to accelerate the growth of our organization, as Matt will focus on the markets and commercial products that we believe offer the greatest opportunities for creating and enhancing value."
Matt Heindel joins Quidel from Prism Enterprises, Inc., a manufacturer of patented, therapeutic, heat-producing packs and vacuum and pressure pumps, which are marketed to healthcare professionals including obstetricians, distributors, as well as to retail outlets. At Prism, Heindel was vice president, sales and marketing and was responsible for the business development as well as customer service functions. Prior to Prism, Heindel served in various sales and marketing capacities at McGaw, Inc., a developer, manufacturer and marketer of intravenous solutions and related products. At McGaw (which formerly was a subsidiary of IVAX and was sold in 1997 to B. Braun Melsungen AG), Heindel was most recently vice president, international. In this capacity, Heindel developed and implemented a global strategy for increasing sales, which included establishing distribution companies, licensing partnerships, and manufacturing facilities in key geographies.
Heindel received his Bachelor of Science degree in Psychology from California State College University, Bakersfield, Calif.
Quidel Corporation is a global company dedicated to helping women and their families live healthy lives through the discovery, development, manufacture and marketing of rapid point-of-care (POC) diagnostic tests. These tests detect medical conditions and illnesses associated with women's health in areas such as reproduction and diseases of the elderly. Quidel also provides POC diagnostic tests for infectious diseases, including influenza A & B, Strep throat, H. pylori infection, Chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's diagnostic tests provide information that results in rapid treatment, improved health outcomes, lowered costs and increased patient satisfaction. Quidel's products are sold for use in physician offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label products. For more information visit www.quidel.com
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risk and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in operating results may arise as a result of a number of factors including, without limitation, seasonality, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration ("FDA"), intellectual property, product liability, environmental or other litigation, and the lower acceptance of our new products than forecast. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate" and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision of the forward-looking statements.
CONTACT: Quidel Corporation
SOURCE: Quidel Corporation